We are live on ! Find out more
WHWK

Whitehawk Therapeutics
WHWK

15 hedge funds and large institutions have $47.5M invested in Whitehawk Therapeutics in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.97% more ownership

Funds ownership: 0% → 1.97% (+2%)

Holders
15
Holders Change
+15
Holders Change %
–
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$20.9M
2
AG
Artal Group
Luxembourg
+$6.28M
3
SFM
Sphera Funds Management
Israel
+$4.45M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.54M
5
TCM
Tekla Capital Management
Massachusetts
+$3.08M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$21.6M +$20.9M +346,263 New
AG
2
Artal Group
Luxembourg
$6.47M +$6.28M +103,893 New
SFM
3
Sphera Funds Management
Israel
$4.58M +$4.45M +73,570 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$3.65M +$3.54M +58,607 New
TCM
5
Tekla Capital Management
Massachusetts
$3.17M +$3.08M +51,000 New
GPCM
6
Granite Point Capital Management
Massachusetts
$3.11M +$3.02M +50,000 New
CH
7
CVI Holdings
Delaware
$1.87M +$1.82M +30,045 New
NC
8
Nexthera Capital
New York
$1.24M +$1.2M +19,925 New
Millennium Management
9
Millennium Management
New York
$934K +$907K +15,000 New
MCM
10
Moore Capital Management
New York
$415K +$403K +6,667 New
NRS
11
Neville Rodie & Shaw
New York
$415K +$403K +6,667 New
HighTower Advisors
12
HighTower Advisors
Illinois
$52K +$50.4K +833 New
TI
13
Truepoint Inc
Ohio
$42K +$41.2K +681 New
AWP
14
Ascent Wealth Partners
New York
$41K +$40.3K +667 New
TRCT
15
Tower Research Capital (TRC)
New York
– +$423 +7 New

WHWK Hedge Fund Activity: Q2 2018 in Review

15 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2018, worth a combined $47.5M.

Buyers outnumbered sellers: 15 funds opened new WHWK positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $20.9M.

  • 15 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2018, up from 0 in Q1 2018.
  • Funds reported $47.5M of Whitehawk Therapeutics stock for Q2 2018.
  • 15 funds opened new Whitehawk Therapeutics positions in Q2 2018 and 0 closed out, a net change of +15 holders.
  • The largest Whitehawk Therapeutics buyer in Q2 2018 was OrbiMed, an estimated $20.9M added.

Based on aggregated 13F filings for Q2 2018.